Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01345812
Other study ID # 20090169
Secondary ID
Status Terminated
Phase Phase 4
First received April 29, 2011
Last updated September 13, 2012
Start date April 2011
Est. completion date August 2012

Study information

Verified date September 2012
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Denmark: Ethics CommitteeDenmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

The primary purpose of the investigation is to identify differences in embryo development after follicle stimulation with two different gonadotrophins.


Description:

So far the assessment of the development potential of the single embryo has been limited by the vulnerability of the embryos when exposed to fluctuations in temperature and CO2 levels.

Thus embryos can only be allowed to leave incubators for a very limited time period.

However, with the development of time-lapse systems for clinical use it is possible to make continuous time-lapse recordings of embryos while they are in a safe incubator environment.

The embryos are not compromised, but the entire embryonic development can still be seen, and will subsequently provide new and essential information on the competence of the single embryo.

Based on the above it is expected that the probability of selecting the most viable and competent embryo is increased, which, in turn, will increase the success rate for couples seeking infertility treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 291
Est. completion date August 2012
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 21 Years to 45 Years
Eligibility Inclusion Criteria:

Participants(heterosexuals, lesbian couples and single women) must sign a document of informed consent

- Female age 21-45 years(both inclusive)

- Patients for IVF treatment

- Regular menstrual cycle 21-35 days(both inclusive)

- Normal FSH levels(1-15 IU/L)

- BMI between 18-32(both inclusive)

- Patients must be able to read and understand patient information in national language

Exclusion Criteria:

PCO

- Endometriosis as primary diagnosis

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Patients for In Vitro Fertilization(IVF)Treatment

Intervention

Drug:
HP-HMG
100 - 300 IU for stimulation of women in ART treatment
recombinant FSH
100 -300 IU for stimulation of women in ART treatment

Locations

Country Name City State
Denmark The fertility clinic Braedstrup

Sponsors (7)

Lead Sponsor Collaborator
University of Aarhus Aagaard Fertility Clinic, Ferring Pharmaceuticals, Herlev Hospital, Odense University Hospital, The Fertility Clinic Braedstrup Hospital, Trianglen Fertility Clinic

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Top Quality Embryos day 2 The oocytes are inseminated and loaded to the time-lapse instrument and cultured for two days. The embryo developemnt are followed at the movie and the embryos are scored according to a standard scoring criteria at 44 h after insemination 44 h after insemination No
Secondary Implantation rate The pregnancy is verified by a blood sample two weeks after embryo transfer and the number of embryos implanted are verified by ultrasound scanning five weeks after embryo transfer. 5 weeks after embryo transfer No

External Links